Does dupilumab treatment increase SARS-CoV-2 infection susceptibility?
Dupilumab is approved for the treatment of moderate-to-severe atopic dermatitis. First data from Italy on dupilumab-treated non-infected in high epidemic areas, and current evidence from dupilumab trials, suggest no negative effect of dupilumab regarding viral infections151 with reports on a reduced number of herpes simplex superinfections and less bacterial superinfections.152-154